Key facts
- This page summarizes Garry E. Menzel's Form 4 filing for TCR2 THERAPEUTICS INC..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Dec 2022, 15:44.
Garry E. Menzel - 07 Dec 2022 Form 4 Insider Report for TCR2 THERAPEUTICS INC.
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 07 Dec 2022
- Net transaction value
- -$23,360
- SEC form
- 4
- Accepted by SEC
- 09 Dec 2022, 15:44:15 UTC
- Prior SEC filing
- 07 Dec 2022
- Next SEC filing
- 13 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Margaret Siegel as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Garry E. Menzel filed Form 4 for TCR2 THERAPEUTICS INC. on 09 Dec 2022.
Change
- Previous filing in this sequence was filed on 07 Dec 2022.
- Current net transaction value: -$23,360.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TCRR
transaction
Common Stock
Sale
- Transaction value
- $11,680
- Shares
- -9,111
- Change %
- -4.8%
- Price
- $1.28
- Shares after
- 180,123
- Date
- 07 Dec 2022
- Ownership
- Direct
- Footnotes
- F3
TCRR
transaction
Common Stock
Sale
- Transaction value
- $11,680
- Shares
- -9,314
- Change %
- -5.2%
- Price
- $1.25
- Shares after
- 170,809
- Date
- 08 Dec 2022
- Ownership
- Direct
- Footnotes
- F3
TCRR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 132,729
- Date
- 07 Dec 2022
- Ownership
- See Footnote
- Footnotes
- F1
TCRR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 132,730
- Date
- 07 Dec 2022
- Ownership
- See Footnote
- Footnotes
- F2
TCRR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 189,234
- Date
- 07 Dec 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Consists of 132,729 shares of common stock held by the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Menzel Trust"). The reporting person is the trustee of the Menzel Trust, and as such the reporting person may be deemed to beneficially own such securities. The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust.
Footnote F2
Consists of 132,730 shares of common stock held by and the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own such securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust.
Footnote F3
The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.